{"url_path":"/sec/jsprw/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-056595-index.html","accession_number":"0001213900-26-056595","cik":"0001788028","ticker":"JSPR","issuer_name":"Jasper Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-056595-index.html","primary_entity_key":"0001788028","primary_entity_name":"Jasper Therapeutics, Inc."},"word_count":370,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nExhibit\n\nNumber\n \nDescription\n \nRegistrant’s\nForm\n \nDate Filed\n\nwith the\n\nSEC\n \nExhibit\nNumber\n\n3.1\n \n[Second Amended and Restated Certificate of Incorporation of the Registrant, dated September 24, 2021.](http://www.sec.gov/Archives/edgar/data/1788028/000121390021050592/ea147929ex3-1_jasper.htm)\n \n8-K\n \n9/29/2021\n \n3.1\n\n \n \n \n \n \n \n \n \n \n\n3.2\n \n[Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, dated June 8, 2023.](http://www.sec.gov/Archives/edgar/data/1788028/000121390023047446/ea179979ex3-1_jasper.htm)\n \n8-K\n \n6/8/2023\n \n3.1\n\n \n \n \n \n \n \n \n \n \n\n3.3\n \n[Certificate of Second Amendment to the Second Amended and Restated Certificate of Incorporation of Jasper Therapeutics, Inc. January 3, 2024.](http://www.sec.gov/Archives/edgar/data/1788028/000121390024000980/ea191024ex3-1_jasper.htm)\n \n8-K\n \n1/3/2024\n \n3.1\n\n \n \n \n \n \n \n \n \n \n\n3.4\n \n[Third Amended and Restated Bylaws of the Registrant.](http://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/ea173877ex3-1_jasper.htm)\n \n8-K\n \n2/17/2023\n \n3.1\n\n \n \n \n \n \n \n \n \n \n\n4.1\n \n[Form of Warrant Agreement, dated November 19, 2019, by and between the Registrant and Continental Stock Transfer & Trust Company, as warrant agent.](http://www.sec.gov/Archives/edgar/data/1788028/000121390019024606/f8k1119ex4-1_amplitude.htm)\n \n8-K\n \n11/25/2019\n \n4.1\n\n \n \n \n \n \n \n \n \n \n\n4.2\n \n[Specimen Warrant Certificate.](http://www.sec.gov/Archives/edgar/data/1788028/000121390019022224/fs12019a1ex4-3_amplitude.htm)\n \nS-1/A\n \n11/6/2019\n \n4.3\n\n \n \n \n \n \n \n \n \n \n\n4.3\n \n[Form of Pre-Funded Warrant to Purchase Common Stock.](http://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/ea025802601ex4-1_jasper.htm)\n \n8-K\n \n9/19/2025\n \n4.1\n\n \n \n \n \n \n \n \n \n \n\n4.4\n \n[Form of Common Warrant.](http://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/ea025802601ex4-2_jasper.htm)\n \n8-K\n \n9/19/2025\n \n4.2\n\n \n \n \n \n \n \n \n \n \n\n31.1*\n \n[Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.](ea028947701ex31-1.htm)\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n31.2*\n \n[Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.](ea028947701ex31-2.htm)\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n32.1**\n \n[Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea028947701ex32-1.htm)\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n101.INS*\n \nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n101.SCH*\n \nInline XBRL Taxonomy Extension Schema Document.\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n101.CAL*\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document.\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n101.DEF*\n \nInline XBRL Taxonomy Extension Definition Linkbase Document.\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n101.LAB*\n \nInline XBRL Taxonomy Extension Label Linkbase Document.\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n101.PRE*\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document.\n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n104*\n \nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).\n \n \n \n \n \n \n\n \n\n*Filed\nherewith.\n\n \n\n**Furnished\nherewith.\n\n \n\n45\n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \nJASPER\nTHERAPEUTICS, INC.\n\n \n \n\nDate: May 14,\n2026\nBy:\n/s/\nJeet Mahal\n\n \n \nJeet Mahal\n\n \n \nPresident and Chief\nExecutive Officer\n\n \n \n*(Principal Executive\nOfficer)*\n\n \n \n\nDate: May 14, 2026\nBy:\n/s/\nHerb Cross \n\n \n \nHerb Cross \n\n \n \nChief Financial Officer\n\n \n \n*(Principal Accounting\nand Financial Officer)*\n\n \n\n \n\n46"}